Transplants for the elderly in myeloma

Blood

Volumn 122, Issue 8, 2013, Pages 1332-1334

  Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; DRUG DERIVATIVE; LENALIDOMIDE; PYRAZINE DERIVATIVE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; DRUG SAFETY; FLOW CYTOMETRY; GERIATRIC DISORDER; HUMAN; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE; FEMALE; MALE; METHODOLOGY; MULTIPLE MYELOMA; NOTE; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MELPHALAN; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE;

EID: 84886807937     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-510941     Document Type: Short Survey

References (10)

1. Gay F, Magarotto V, Crippa C., et al. Bortezomib induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013; 122(8): 1376-1383.
2. Morgan GJ, Davies FE, Gregory W.M., et al.; NCRI Haematological Oncology Study Group. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011; 118(5): 1231-1238.
3. Facon T, Mary JY, Hulin C, et al.; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007; 370(9594): 1209-1218. (Pubitemid 47516593)
4. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council myeloma IX study. J Clin Oncol. 2013; 31(20): 2540-2547.
5. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12(5): 335-348.
6. Barlogie B, Anaissie E, van Rhee F, et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007; 20(4): 761-781. (Pubitemid 350215382)
7. Attal M, Harousseau JL, Facon T, et al.; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med. 2003; 349(26): 2495-2502. (Pubitemid 38010075)
8. Child JA, Morgan GJ, Davies F.E., et al.; Medical Research Council Adult Leukaemia Working Party. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348(19): 1875-1883. (Pubitemid 36532313)
9. Sonneveld P, van der Holt B, Segeren CM, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 2007; 92(7): 928-935. (Pubitemid 350144239)
10. Cavo M, Tosi P, Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007; 25(17): 2434-2441. (Pubitemid 46999214)